On Wednesday, Stifel, a financial services firm, adjusted its price target for X4 Pharmaceuticals (NASDAQ: NASDAQ:XFOR), a clinical-stage biopharmaceutical company, to $4.00 from the previous $5.00. Despite the decrease, Stifel continues to recommend a Buy rating for the company's stock.
The adjustment comes amid observations of the recent performance of X4's product, XOLREMDI, which is used in the treatment of WHIM syndrome, a rare genetic immunodeficiency disorder. The analyst noted that while the launch of XOLREMDI was anticipated to be a critical event for investors, its sales remained flat at $0.6 million for the second quarter of 2024. This stagnation suggests that the sales figures could be attributed to inventory accumulation rather than new patient starts.
Furthermore, the analyst pointed out that the rate of patient screening and onboarding appears to be significantly slower than expected by both the company and market analysts. This slow progress is particularly concerning as it may limit the potential of XOLREMDI's revenue to act as a short-term catalyst or to provide financial support to the company's balance sheet. X4 Pharmaceuticals is deemed to need such support before the expected year-end 2026 top-line Phase 3 data for chronic neutropenia (CN), another condition for which XOLREMDI is being evaluated.
The report also highlighted that while the Phase 2 data for CN continues to be promising, indicating the drug's potential real-world application, the revised price target primarily reflects lower projected revenues from XOLREMDI for the fiscal year 2024 and beyond, as well as updated financing assumptions.
InvestingPro Insights
Recent InvestingPro data provides additional context to X4 Pharmaceuticals' financial situation and market performance. The company's market capitalization stands at $47.69 million, reflecting its current valuation in the biotech sector. Despite the challenges highlighted in the Stifel report, X4 has shown a strong return over the last month, with a 15.71% price total return.
InvestingPro Tips reveal that X4 Pharmaceuticals holds more cash than debt on its balance sheet, which could be crucial as the company navigates the slow uptake of XOLREMDI. However, the company is also quickly burning through cash, a common characteristic of clinical-stage biopharmaceutical firms investing heavily in research and development.
The fair value based on analyst targets is $5.00, significantly higher than the current trading price, aligning with Stifel's maintained Buy rating despite the lowered price target. It's worth noting that InvestingPro offers 8 additional tips for X4 Pharmaceuticals, providing a more comprehensive analysis for investors considering the stock's potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.